LXRX

Wedbush Makes Big Changes to Best Ideas List for October

With the third-quarter earnings reports ready to start rolling out fast and furious, many of the top analysts we follow on Wall Street are making some changes to the lists ...
Read Full Story »

Equifax, New York REIT Dive into Thursday’s 52-Week Low Club

September 14, 2017: Here are four stocks trading with heavy volume among 24 equities making new 52-week lows in Thursday's session. On the NYSE, advancers led decliners by about 15 ...
Read Full Story »

Equifax, HP Enterprise Tumble into Wednesday’s 52-Week Low Club

September 13, 2017: Here are four stocks trading with heavy volume among 26 equities making new 52-week lows in Wednesday's session. On the NYSE, advancers led decliners by about 8 ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna, Lexicon Pharma and Many More

Stocks were indicated to open slightly lower on Monday after some of the top momentum and crowded technology companies took it on the chin on Friday. Still, a rotation took ...
Read Full Story »

Lexicon Pharmaceuticals Rises on Late-Stage Diabetes Trial

Shares of Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) saw a hand gain early on Friday after the company reported top-line results from its late-stage trial in type-1 diabetes. Specifically, Lexicon announced ...
Read Full Story »
graph

Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential

Needless to say, the biotech world has had a very difficult 18 months. Even the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, have ...
Read Full Story »
buy sell

Top Analysts Upgrades and Downgrades: Abbott Labs, General Dynamics, Nexstar Media, Owens Corning, Palo Alto Networks, Salesforce and More

The futures are looking much higher this morning after a very positive speech from President Donald Trump to a joint session of Congress last night. Trump's big spending plans and ...
Read Full Story »
thumbs up

Wedbush’s 6 Best Idea Stocks for 50% Upside (or Much More)

Markets recently reached their all-time highs and have pulled back slightly, with the Dow Jones Industrial Average just crossing under 20,000 after it made historic run. Some analysts are taking ...
Read Full Story »
FDA_logo

6 Major FDA Decisions and Biopharma Catalysts Coming in January and February

Companies that reside within the biotech and pharmaceutical industries are subject to a sizable amount of risk in regards to their drug candidates passing clinical trials and gaining regulatory approval. ...
Read Full Story »
FDA_logo

7 Key FDA Decisions and Catalysts Expected in January and February

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a ...
Read Full Story »
FDA_logo

10 Major Pharma and FDA Catalysts Coming in December

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a ...
Read Full Story »
clinical trials

4 Key BioPharma Movers in the Past Week

A few biotech companies made impressive runs over the course of this past week. In the past 52 weeks, biotech and pharmaceutical stocks have been absolutely crushed. However the year ...
Read Full Story »
Prescription drugs

Why Lexicon Pharma Is Soaring

Shares of Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) saw a handy gain on Friday after late-stage results came out. The company announced that its pivotal inTandem1 Phase 3 clinical trial of sotagliflozin ...
Read Full Story »
fda_logo

4 New Big FDA Decisions Expected in September

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, similar to that ...
Read Full Story »
ten dollars

8 Analyst Stocks Under $10 With Massive Upside Calls

This past week was a break from the endless, six-year bull market. Still, the market remains effectively at all-time highs, and investors have bought every single dip for close to ...
Read Full Story »